The higher barrier of darunavir and tipranavir resistance for HIV-1 protease

Biochemical and Biophysical Research Communications

Volumn 412, Issue 4, 2011, Pages 737-742

  Wang, Yong ^a   Liu, Zhigang ^a   Brunzelle, Joseph S ^b   Kovari, Iulia A ^a   Dewdney, Tamaria G ^a   Reiter, Samuel J ^a   Kovari, Ladislau C ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Darunavir; Multi drug resistant HIV 1 protease; Tipranavir; X ray crystallography

Indexed keywords

AMPRENAVIR; ASPARAGINE; ASPARTIC ACID; ATAZANAVIR; DARUNAVIR; GLYCINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; INDINAVIR; ISOLEUCINE; LOPINAVIR; MULTIDRUG RESISTANT HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; NELFINAVIR; PROLINE; RITONAVIR; SAQUINAVIR; THREONINE; TIPRANAVIR; UNCLASSIFIED DRUG; VALINE;

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; IC 50; IN VITRO STUDY; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; WILD TYPE;

AMINO ACID SEQUENCE; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MOLECULAR SEQUENCE DATA; MUTATION; PYRIDINES; PYRONES; SULFONAMIDES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80052636995     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.08.045     Document Type: Article

References (22)

1. Shafer R.W. Rationale and uses of a public HIV drug-resistance database. J. Infect. Dis. 2006, 194(Suppl. 1):S51-S58.
2. Rhee S.Y., Gonzales M.J., Kantor R., Betts B.J., Ravela J., Shafer R.W. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 2003, 31:298-303.
3. Rhee S.Y., Taylor J., Fessel W.J., Kaufman D., Towner W., Troia P., Ruane P., Hellinger J., Shirvani V., Zolopa A., Shafer R.W. HIV-1 protease mutations and protease inhibitor cross resistance. Antimicrob. Agents Chemother. 2010, 54:4253-4261.
4. Palmer S., Shafer R.W., Merigan T.C. Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS 1999, 13:661-667.
5. Logsdon B.C., Vickrey J.F., Martin P., Proteasa G., Koepke J.I., Terlecky S.R., Wawrzak Z., Winters M.A., Merigan T.C., Kovari L.C. Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity. J. Virol. 2004, 78:3123-3132.
6. Yedidi R.S., Proteasa G., Martinez J.L., Vickrey J.F., Martin P.D., Wawrzak Z., Liu Z., Kovari I.A., Kovari L.C. Contribution of the 80s loop of HIV-1 protease to the multidrug-resistance mechanism: crystallographic study of MDR769 HIV-1 protease variants. Acta crystallogr. D Biol. Crystallogr. 2011, 67:524-532.
7. Tenore S.B., Ferreira P.R. The Place of protease inhibitors in antiretroviral treatment. Braz. J. Infect. Dis. 2009, 13:371-374.
8. Temesgen Z., Feinberg J. Tipranavir: a new option for the treatment of drug-resistant HIV infection. Clin. Infect. Dis. 2007, 45:761-769.
9. Ghosh A.K., Dawson Z.L., Mitsuya H. Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV. Bioorg. Med. Chem. 2007, 15:7576-7580.
10. Streeck H., Rockstroh J.K. Review of tipranavir in the treatment of drug-resistant HIV. Ther. Clin. Risk Manag. 2007, 3:641-651.
11. Welch M., Govindarajan S., Ness J.E., Villalobos A., Gurney A., Minshull J., Gustafsson C. Design parameters to control synthetic gene expression in Escherichia coli. PLoS One 2009, 4:e7002.
12. Vickrey J.F., Logsdon B.C., Proteasa G., Palmer S., Winters M.A., Merigan T.C., Kovari L.C. HIV-1 protease variants from 100-fold drug resistant clinical isolates: expression, purification, and crystallization. Protein Express. Purif. 2003, 28:165-172.
13. Niesen F.H., Berglund H., Vedadi M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat. Protoc. 2007, 2:2212-2221.
14. Liu Z., Wang Y., Brunzelle J., Kovari I.A., Kovari L.C. Nine crystal structures determine the substrate envelope of the MDR HIV-1 protease. Protein J. 2011, 30:173-183.
15. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods in Enzymology 1997, 307-326. Academic Press, Inc., New York, NY. C.W. Carter, R.M. Sweet (Eds.).
16. Collaborative Computational Project Number 4, The CCP4 suite: programs for protein crystallography, Acta Crystallogr. D Biol. Crystallogr. 50 (1994) 760-763.
17. Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 2004, 60:2126-2132.
18. Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Cryst. 1993, 26:283-291.
19. Wallace A.C., Laskowski R.A., Thornton J.M. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 1995, 8:127-134.
20. Liu T.F., Shafer R.W. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin. Infect. Dis. 2006, 42:1608-1618.
21. Ghosh A.K., Chapsal B.D., Weber I.T., Mitsuya H. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance. Accounts Chem. Res. 2008, 41:78-86.
22. Tie Y., Boross P.I., Wang Y.F., Gaddis L., Hussain A.K., Leshchenko S., Ghosh A.K., Louis J.M., Harrison R.W., Weber I.T. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. J. Mol. Biol. 2004, 338:341-352.